Drug interactions
Deferasirox + Glimepiride-pioglitazone
Severity: Minor
Deferasirox and Glimepiride-pioglitazone: minor interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Deferasirox can induce CYP3A4 and inhibit CYP2C8, so its net effect on pioglitazone exposure is uncertain. Inhibition of CYP2C8 could raise pioglitazone levels and increase fluid retention or hypoglycemia.
What this interaction means in plain words
Deferasirox and Glimepiride-pioglitazone have a small, usually unimportant interaction. Most people can take both; the pharmacist may still mention it so that any unexpected effect is recognised.
Deferasirox belongs to Miscellaneous; Glimepiride-pioglitazone belongs to Endocrine.
Why it happens
Opposing effects on pioglitazone metabolism: CYP3A4 induction and CYP2C8 inhibition.
What to do
Monitor glycemic control and signs of fluid retention when deferasirox is started or stopped.
What to ask your pharmacist
- Is there anything I should notice while taking both?
- Do I need to tell my doctor at the next visit?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Deferasirox and Glimepiride-pioglitazone, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 7 days on the web. No card needed.
Other interactions of Glimepiride-pioglitazone
Other interactions of Deferasirox
Frequently asked questions
Can I take Deferasirox with Glimepiride-pioglitazone?
MediHelp rates the interaction as minor. Deferasirox and Glimepiride-pioglitazone have a small, usually unimportant interaction. Most people can take both; the pharmacist may still mention it so that any unexpected effect is recognised. Deferasirox can induce CYP3A4 and inhibit CYP2C8, so its net effect on pioglitazone exposure is uncertain. Inhibition of CYP2C8 could raise pioglitazone levels and increase fluid retention or hypoglycemia.
How serious is the interaction between Deferasirox and Glimepiride-pioglitazone?
MediHelp rates it minor, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Monitor glycemic control and signs of fluid retention when deferasirox is started or stopped.
What other medicines interact with Glimepiride-pioglitazone?
MediHelp also lists interactions of Glimepiride-pioglitazone with, for example, Fluconazole, Gemfibrozil, Insulin aspart. The full list is on the Glimepiride-pioglitazone page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
